Clinical Data Arthrosi drug trial in gout delivers for new owner Sobi PharmaphorumSobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.Immunology & InflammationRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) Pharmaphorum Sobi’s $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad. Immunology & Inflammation Read full story Post navigation Previous: Lilly’s Verve gambit pays off as base editor cuts cholesterol in early studyNext: Eli Lilly to buy trio of vaccine developers in $3.8bn outlay Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026